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Abstract
Background: Postpartum haemorrhage (PPH) can be exacerbated by haemostatic failure. We hypothesized that early fibrino-
gen replacement, guided by viscoelastometric testing, reduces blood product usage and bleed size.
Methods:Women with PPH 1000–1500ml were enrolled. If Fibtem A5 was 15mm and bleeding continued, subjects were
randomized to fibrinogen concentrate or placebo. The primary outcome compared the number of units of red blood cells,
plasma, cryoprecipitate and platelets transfused.
Results: Of 663 women enrolled 55 were randomized. The adjusted incidence rate ratio (IRR) (95% CI) for the number of alloge-
neic units transfused in the fibrinogen group comparedwith placebo was 0.72 (0.3–1.7), P¼0.45. In pre-specified subgroup analy-
ses, subjects who had a FibtemA512mm at the time of randomization and who received fibrinogen concentrate received a
median (25th–75th centile) of 1 (0–4.5) unit of allogeneic blood products and had an additional 300 (100–350)ml blood loss
whereas those who received placebo also received 3 (0–6) units of allogeneic blood products and had 700 (200–1550)ml addi-
tional blood loss; these differences were not statistically significantly different. There was one thrombotic event in each group.
Conclusions: Infusion of fibrinogen concentrate triggered by Fibtem A515mm did not improve outcomes in PPH.
Pre-specified subgroup analyses suggest that fibrinogen replacement is not required if the Fibtem A5 is>12mm or Clauss
fibrinogen >2g litre1, but an effect below these levels cannot be excluded. The raised fibrinogen at term appears to be a
physiological buffer rather than required for haemostasis.
Editorial decision: May 1, 2017; Accepted:May 25, 2017
VC The Author 2017. Published by Oxford University Press on behalf of the British Journal of Anaesthesia.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
1
British Journal of Anaesthesia, 0 (0): 1–11 (2017)
doi: 10.1093/bja/aex181
Clinical Investigation
Trial registration: ISRCTN46295339 (http://www.isrctn.com/ISRCTN46295339, last accessed 5 July 2017), EudraCT
2012-005511-11 (https://www.clinicaltrialsregister.eu/ctr-search/search?query¼2012-005511-11, last accessed 5 July 2017).
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Postpartum haemorrhage (PPH) is the leading cause of maternal
mortality and severe maternal morbidity worldwide,1 2 and its
incidence is increasing in many countries.3–6 Bleeding is precipi-
tated by obstetric causes but can be exacerbated by haemostatic
impairment.7 8 At term, the haemostatic system is prothrom-
botic7 9 with fibrinogen concentrations of 4–6g litre1 compared
with 2–4g litre1 in the non-pregnant population.10 11 Fibrinogen
decreases earlier than other coagulation factors during PPH,12 13
suggesting a potentially important role in haemostasis.
Fibrinogen <3g litre1, measured early during PPH, is associated
with progression to massive haemorrhage, red blood cell (RBC)
and fresh frozen plasma (FFP) transfusion, invasive procedures
and level 2/3 admission. Fibrinogen >4 g litre1 is less often asso-
ciated with progression of bleeding.12 14–17 During PPH, it is
unknown whether fibrinogen should be maintained at a level
that is normal for term (>4 g litre1), above the non-pregnant
range (>2g litre1) or an intermediate level (3 g litre1).
The clinical utility of laboratory fibrinogen to predict pro-
gression of PPH is limited because results take 60–90min to
become available.18 A point-of-care viscoelastometric test,
RotemV
R
(Tem International, Munich, Germany) provides a
Fibtem A5 result within 10min. Fibtem correlates with labora-
tory fibrinogen during PPH,19 and in an observational study
A515mm was usually associated with progression of PPH
whereas A5 >22mmwas not.14 To study the appropriate level of
fibrinogen-related haemostasis required during PPH, we investi-
gated whether fibrinogen replacement improved outcomes if
Fibtem A5 was 15mm (fibrinogen about 3 g litre1).
Methods
This was a multicentre, randomized, double-blind, placebo-con-
trolled trial set in teaching hospital obstetric units. It was
approved by the Edinburgh Multicentre Research Ethics
Committee (13/SS/0008). Trial registration: ISRCTN46295339
(http://www.isrctn.com/ISRCTN46295339, last accessed 5 July
2017), EudraCT 2012-005511-11 (https://www.clinicaltrialsregister.
eu/ctr-search/search?query¼2012-005511-11, last accessed 5 July
2017). The protocol has been published.20
Women aged 18yr and 24weeks gestation who had
ongoing major PPH (1000–1500ml blood loss) could be enrolled.
Women were excluded if they declined transfusion, had placenta
accreta diagnosed antenatally, had undergone an invasive proce-
dure to control bleeding or if there was clinical suspicion of amni-
otic fluid embolus. Detailed inclusion and exclusion criteria have
been published.20 Women received written information in their
maternity notes. Verbal consent was sought at enrolment and
confirmed in writing when the woman had recovered from the
bleed. At study entry, a Fibtem was performed in the delivery
suite and samples were sent to the laboratory for full blood count,
Clauss fibrinogen, prothrombin time (PT) and activated partial
thromboplastin time (aPTT). Blood loss was measured gravimetri-
cally as described.21 Local standard treatment was instituted
except that FFP was not infused if the Fibtem A5was >15mm.
Fibtem was repeated after each additional 500ml blood loss or
for clinical concern. If the A5 was15mm, the baby delivered and
bleeding ongoing the woman was randomized. Randomization
and blinding procedures are published.20 Study medication was
fibrinogen concentrate (Riastap, Marburg, Germany) or placebo
(normal saline, Fresenius Kabi AG, Homburg, Germany). The
study design is shown in the Supplementary data, Figure S1. The
method for mixing and blinding the fibrinogen and placebo using
an opaque cover is published.22 Vials contained either 1g of fibri-
nogen in 50ml of water or 50ml of normal saline. The dose of
fibrinogen or placebo infused was calculated according to:
ðnumber of vialsÞ ¼ ð23 – Fibtem A5Þ x ideal body weight for height=140
rounded to the nearest 1 g. Investigators had a chart with pre-
calculated doses.20 The aim was to increase Fibtem A5 to
>22mm in the fibrinogen arm. At randomization 1g of tranexa-
mic acid was infused if not already given and 4 units of FFP
ordered. Some or all of the FFP was infused when it arrived if
bleeding was ongoing or there had been an additional 500ml of
blood loss since randomization. If bleeding stopped further FFP
could be withheld. Fibtem and coagulation screens were per-
formed 15min after study medication. These results were not
available to the treating clinicians until after the decision to give
FFP had been made. Subsequent treatment was at the discretion
of treating clinicians. Women were contacted 6weeks after
randomization to record establishment of breastfeeding and
adverse events including thrombosis.
Information was collected through an electronic case report
form.20 The primary endpoint was the number of allogeneic
blood products (RBC, FFP, cryoprecipitate, platelets) infused after
study medication until hospital discharge between the two
randomized arms. Secondary endpoints were: measured
blood loss, numbers of units of RBC, FFP, cryoprecipitate,
and platelet transfusion within the first 24h, cell salvage, change
in Fibtem and Clauss fibrinogen, invasive procedures and initia-
tion of breastfeeding. Safety endpoints were thrombosis to
6weeks, level 2 and 3 admission and length of hospital stay.
Statistical analysis
Based on data collected in a previous study with the same entry
criteria,14 we calculated that 54 women were needed to provide
Editor’s key points
• Severe postpartum haemorrhage can be exacerbated by
coagulopathy, but the role of early targeted fibrinogen
replacement is unknown.
• Women with severe postpartum haemorrhage and
reduced fibrinogen assessed by viscoelastometry were
randomized to receive fibrinogen concentrate or placebo.
• Fibrinogen replacement for moderate reduction in fibri-
nogen did not reduce allogeneic blood product transfu-
sion or blood loss in postpartum haemorrhage.
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80% power at the two-sided 5% level to detect a difference of 3.3
total allogeneic units between groups. We allowed for a 10%
dropout rate and inflated the recruitment target to 60. Full
details of the sample size calculation are published.20
Analyses are intention-to-treat without imputation, with
outcomes compared between groups using mixed-effects two-
level regression models to adjust for site and allow for cluster-
ing. Akaike’s Information Criterion was used to select the best
fitting model. Models were adjusted for two pre-specified con-
founders: Caesarean section and placental abruption. Where
data were skewed, transformations were performed.
For binary outcomes, a logistic model was used and results
presented as adjusted odds ratios (ORs) alongside 95% confidence
intervals (CIs). For continuous outcomes, a linear regression
model was fitted and results presented as difference in adjusted
means (fibrinogen minus placebo) alongside 95% CIs. Count data
were analysed using Poisson multilevel or negative binomial
models if over-dispersion was evident and presented as incident
rate ratios (IRRs). The IRR compares the rate of events (e.g. total
transfused units divided by the number of patients) as a ratio of
fibrinogen to placebo. Where distributions were skewed, a natural
log transformation was performed for regression analysis.
Pre-specified subgroup analyses were conducted on the
primary outcome by inclusion of an interaction term in the
model. As the trial is powered to detect overall differences
between the groups rather than interactions of this kind, the
results of these exploratory analyses are presented using CIs as
well as P-values. Subgroups were:
• Fibtem A5 at randomization 12 or> 12mm
• Fibrinogen at randomization <2 or 2 g L1
• Caesarean section vs vaginal birth
• Platelets <100 or 100 x 109 litre1 at randomization
Analyses were performed by R.C.-J. using SPSS version 20
(IBM SPSS Inc, Chicago, USA) and Stata version 13 (StataCorp
LLC, Texas, USA).
Results
Between June 29, 2013 and November 26, 2015, 663 women from
six centres gave informed consent for study inclusion (Fig. 1).
In total, 57/663 (8.7%) women were randomized. Two of the 57
women were later found to be ineligible for randomization
(in one case the baby was not delivered and in the other case an
invasive radiological procedure had been performed before study
entry); therefore, 55 women were analysed. The 605 women
enrolled, but not randomized, has been reported elsewhere.
Baseline characteristics were balanced between trial groups
(Table 1). The median (25th–75th centile) measured blood loss
was 1450 (1200–1800)ml at enrolment and 1950 (1500–2285)ml
when study medication was infused. Fibtem and fibrinogen at
time of study medication were similar in the two arms (Table 2).
There were no missing data for the primary outcome. Women
in the fibrinogen arm received 58 units (mean transfusion rate of
2.07) of allogeneic blood products compared with 75 units (mean
transfusion rate of 2.78) in the placebo arm, median (25th–75th
centile, range) 1.0 (0–2.75, 0–15) for fibrinogen and 1.0 (0–4, 0–23)
for placebo. There was no evidence of a treatment effect [adjusted
IRR 0.72 (95% CI 0.30–1.70), P¼0.45]. There was no evidence of clus-
tering between sites or in women who had a Caesarean section
(intra-cluster correlation coefficient ¼ –0.031).
Women in the fibrinogen arm received 37 units of RBC com-
pared with 38 units in the placebo arm. The difference in total
allogeneic infusions was therefore due almost entirely to FFP
where 6/28 (21%) women randomized to fibrinogen received a
total of 18 units, and 8/27 (30%) women randomized to placebo
received 33 units IRR 0.53 (0.13–2.16) (Table 3). Blood loss after
study medication was similar between arms (Table 3).
An invasive procedure before studymedication was performed
in 11/28 (39%) and 9/27 (33%) women in the fibrinogen and placebo
groups, respectively. After study medication, invasive procedures
in the fibrinogen and placebo arms were similar (Table 3 and
supplementary Table 1). There was a right pulmonary artery
thrombosis in the fibrinogen arm and a right ovarian vein throm-
bosis in the placebo arm.
Changes in Fibtem, fibrinogen, PT and aPPT following study
medication are shown in Table 2. There was a difference in fibri-
nogen, Fibtem A5 and aPPT between the arms at 15min but not
at 24h. The Fibtem A5 increased to >22mm in 2/28 (7.1%)
women in the fibrinogen group.
Subgroup analyses
Pre-specified subgroup analyses for the primary outcome and
post hoc subgroup analyses for blood loss and time on level 2/3
care are shown in Table 4. At randomization, there were 28
women with Fibtem A512mm and 27 women >12mm. Blood
loss at randomization was similar, median (25th–75th centile)
2000 (1650–2390) and 2000 (1670–2370) in the12mm and
>12mm groups, respectively. Outcomes were indistinguishable
between the fibrinogen and placebo groups in women
randomized with a Fibtem A5 >12mm. Women with A512mm
at randomization who received fibrinogen had fewer allogeneic
blood products, less bleeding (Fig. 2) and less time in level 2/3
care. The overall interaction between treatment arm and Fibtem
A5 was not significant for any outcome.
At randomization, 39 women had a fibrinogen >2 g litre1, 21
received fibrinogen and 18 received placebo. Blood loss at
randomization was median (25th–75th centile) 2350 (2000–2080)
and 1950 (1630–2290) in the <2 g litre1 and 2 g litre1 groups,
respectively. In the women randomized with a fibrinogen >2 g
litre1, outcomes were indistinguishable between arms (Table 4
and Fig. 2). Seven women had fibrinogen <2 g litre1 at
randomization, outcomes are shown in Table 4 and Figure 2.
The overall interaction between treatment arm and fibrinogen
at randomization was not significant for any outcome.
Median fibrinogen at the time of study medication infusion
was 2.5g litre1. Post hoc analysis was performed, investigating
women randomized with a fibrinogen2.5 (n¼24) or>2.5g litre1
(n¼22). In women randomized with a fibrinogen2.5g litre1,
the total allogeneic blood products infused was median (25th–
75th centile) 2 (1–5) units in the fibrinogen arm and 3 (0–5.5) units
in the placebo arm. Women randomized with a fibrinogen >2.5g
litre1 were transfused 0 (0–0) total allogeneic units in both the
fibrinogen and placebo arms. Blood loss after study medication
in women with fibrinogen2.5g litre1 was 300 (165–673)ml in
the fibrinogen arm and 850 (315–1845)ml with placebo. In
women randomized with a fibrinogen >2.5g litre1, blood loss
was 200 (55–1540)ml and 150 (28–300)ml in the fibrinogen and
placebo groups, respectively. When scatter plots of blood loss
and fibrinogen are examined by trial arm (Fig. 2), there appears
to be a differential relationship, but when a linear model was
fitted to transformed (log plus one) data (due to skewed blood
loss data), their interaction was not statistically significant
(difference in logþ 1 means¼1.23, 95% CI: –0.45 to 2.90).
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Randomized
(n=57)
Gave consent and screened
(n=663)
Ineligible (n=1327)
• Bleeding stopped, n=1221
• Already received surgical intervention, n=41                     
• Placenta accreta diagnosed, n=14                                      
• Known inherited bleeding disorder, n=12
• Less than18 yr old, n=10
• Declined red blood cells, n=10
• No reason, n=11    
• Opted out/no consent antenatal, n=2
• Enrolled onto another study, n=6
Ineligible
(Fibtem A5 >15 mm or bleeding stopped after 
enrolment and before randomization)
(n=606)
Outcomes to be reported elsewhere
Eligible (n=2231)
Eligible but not recruited (n=1568) 
• Lack of staff to perform study related procedures,
n=650
• Unable to consent, n=450 
• Declined, n=181
• No reason stated, n=125
• Language barrier, n=111
• Woman too ill or stressed to approach, n=40
• No confirmational consent, n=7 
• Legal representative declined, n=4        
Allocated to placebo (n=28)
• Received allocation, n=27
• Did not receive allocation, n=1
Ineligible for trial
Assessed for eligibility
(with >1litre blood loss)
(n=3894)
Allocated to intervention  (n=29)
• Received allocation, n=28
• Did not receive allocation, n=1
Ineligible for trial
Lost to follow-up (n=0)Lost to follow-up (n=0)
Analysed for primary outcome 
(n=27)
Analysed for primary outcome 
(n=28)
Eligibility unknown (n=336)                                    
Lost to 6 week follow-up (n=2)
could not contact 
Lost to follow-up (n=3)
could not contact 
Fig 1 Consort diagram.
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Discussion
Early infusion of fibrinogen concentrate in women experiencing
moderate to severe PPH who had a Fibtem A515mm did not
lead to a statistically significant reduction in transfusion require-
ments or blood loss. Pre-specified subgroup analyses suggested
that a Fibtem A5 >12mm or fibrinogen >2 g litre1 are adequate
for haemostasis and fibrinogen replacement is not necessary. An
effect of fibrinogen infusion on blood product usage and bleed
size at a Fibtem A512mm or Clauss fibrinogen <2.5g litre1
could not be excluded and should be investigated further.
Studies have shown that fibrinogen <3 g litre1 or Fibtem
A515mm, measured early during a PPH, is associated
with progression to severe bleeding and the need for
Table 1 Baseline maternal characteristics at study entry by trial arm. *Women may have had more than one cause of bleeding. †For multi-
ple pregnancies, the most invasive mode is taken
Variable Fibrinogen
(n¼28)
Placebo
(n¼27)
Demographics
Age at recruitment (yr), mean (range) 30.8 (19–42) 33.5 (20–48)
Ethnicity, n (%)
White 17 (60.7) 22 (81.5)
Other 11 (39.3) 5 (18.5)
BMI at booking, mean (SD) 26.4 (5.40) 25.3 (4.57)
Missing n 0 1
Previous Caesarean section, n (%) 9 (32.1) 9 (33.3)
Pre-eclampsia during this pregnancy, n (%) 3 (10.7) 5 (18.5)
Past history of postpartum haemorrhage, n (%) 5 (17.9) 6 (23.1)
Delivery
Onset of labour, n (%)
Spontaneous 9 (32.1) 9 (33.3)
Induced 4 (14.3) 7 (25.9)
No labour 15 (53.6) 11 (40.7)
Multiple gestation, n (%)
Singleton 24 (85.7) 25 (92.6)
Twins 4 (14) 2 (7.4)
Reported causes of postpartum haemorrhage*, n (%)
Uterine atony 23 (82.1) 16 (59.3)
Surgical bleeding 9 (32.1) 10 (37.0)
Trauma 6 (21.4) 4 (14.8)
Retained placenta 1 (3.6) 5 (18.5)
Placental abruption 2 (7.1) 3 (11.1)
Placental praevia 1 (3.6) 2 (7.4)
Undiagnosed placenta accrete 0 (0) 1 (3.7)
Mode of delivery†, n (%)
Spontaneous vaginal 7 (25) 6 (22.2)
Instrumental vaginal 3 (10.7) 4 (14.8)
Elective Caesarean section 10 (35.7) 9 (33.3)
Non-elective Caesarean section 8 (28.6) 8 (29.6)
Blood loss
Estimated blood loss at study entry (ml), median (25th–75th centiles) 1400 (1200–1575) 1500 (1000–2000)
Measured blood loss at administration of study medication (ml), median (25th–75th centiles) 1950 (1500–2280) 2000 (1700–2500)
Haemoglobin at study entry (g litre–1), median (25th–75th centiles) 94.5 (86.3–108.8) 101 (73.0–108.0)
Time (min) from Fibtem triggering randomization to administration of study medication, median
(25th–75th centiles)
24 (20–33) 26 (18–40)
Interventions
Patients receiving at least one invasive procedure after study entry and prior to administration
of study medication, n (%)
11 (39.3) 9 (33.3)
Crystalloid transfusion prior to administration of study medication (ml), median (25th–75th
centiles)
2000 (2000–3375) 3000 (1875–4000)
Missing 0 1
Colloid transfusion prior to administration of study medication (ml), median (25th–75th centiles) 500 (0–500) 500 (500–1000)
Missing 1 2
Patients transfused red blood cells prior to administration of study medication, n (%), median
units (25th–75th centiles)
8 (28.6) 9 (33.3)
0 (0–3) 0 (0–1.75)
Patients transfused fresh frozen plasma prior to administration of study medication, n (%) 0 (0.0) 0 (0.0)
Patients transfused platelets prior to administration of study medication, n (%) 0 (0.0) 2 (7.4)
Patients transfused cryoprecipitate prior to administration of study medication, n (%) 0 (0.0) 0 (0.0)
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blood transfusion.12 14–17 Our study investigated whether early
correction of Fibtem/fibrinogen at these levels would improve
outcomes. The results show that 15mm is too high as an inter-
ventional trigger. Subgroup analyses suggest that A5 >12mm or
fibrinogen >2 g litre1 is adequate for haemostasis during PPH
and that fibrinogen replacement is not necessary.
These conclusions build on a previous double-blind
randomized controlled trial in which 2g of fibrinogen concentrate
or placebo was infused after 1500ml blood loss. There were no
differences in any outcomes measured.23 It was established retro-
spectively that the fibrinogen level when study drug was infused
was mean (SD) 4.5 (1.1) g litre1, confirming that this level of fibri-
nogen is adequate for haemostasis during PPH and suggesting
that a non-targeted, empirical approach to fibrinogen replace-
ment is unlikely to be an optimal and cost-effective strategy.
An observational, non-randomized, open-label study
described women with moderate PPH and a Fibtem A5 <7 or
<12mm with severe bleeding, (fibrinogen about 1.2 and 2.2 g
litre1, respectively) who were infused 3 g fibrinogen concen-
trate that could be repeated if required. Compared with
formulaic replacement in the ratios RBC:FFP:platelets 4:4:1,
fewer women required >5 units of RBCs and transfusion-
associated circulatory overload and intensive care unit
admissions decreased.24 25 Our study also suggests that a fibri-
nogen intervention trigger of about 2 g litre1 is appropriate in
severe PPH. In our study, blood product usage and bleeding
decreased progressively in the fibrinogen arm compared with
placebo as the fibrinogen level at randomization decreased
suggesting a continuum effect.
The optimum fibrinogen level for intervention during PPH
has been debated because fibrinogen at term (>4 g litre1) is
higher than in the healthy non-pregnant population (2–4 g
litre1). In our study, the target Fibtem A5 was 22mm (fibrino-
gen about 4 g litre1) because this was associated with limited
progression of bleeding in an observational study.14 This target
Fibtem was not achieved in most women, probably because
fibrinogen continued to be consumed. This is unlikely to have
affected the study outcome because there was no benefit from
infusing fibrinogen if the level was above 2–2.5 g litre1 and
infusing fibrinogen concentrate when the fibrinogen is 4 g
litre1 has no effect.23 Increased fibrinogen at term appears
to be a physiological buffer rather than a requirement for
haemostasis. Recently updated guidelines incorporate this
finding.26–28
Fibrinogen <2 g litre1 is uncommon during PPH. In a
prospective observational study of 1951 women, fibrinogen
concentration at admission was 5.3 g litre1 and did not predict
severe PPH.29 In two consecutive cohorts of >24 000 women, of
those with bleeds between 1000 and 2000ml, a fibrinogen <2 g
litre1 was seen in 1–2 per 1000 deliveries.13 14 The likelihood
of a woman having a fibrinogen <2 g litre1 depended on the
cause and size of the bleed. It was uncommon at 1000–2000ml
blood loss due to atony and surgical bleeding,14 but occurred in
60% of 6000ml bleeds.30 Fibrinogen <2 g litre1 was more com-
mon with smaller bleeds associated with placental abruption
and amniotic fluid embolus14 29 due to consumptive coagulo-
pathies.31 32
In our study, Fibtem A5 remained >15mm and PT and aPTT
normal in >90% of cases with bleeding controlled without hae-
mostatic support. This suggests that early, formulaic and liberal
use of FFP, based on practice extrapolated from major trauma,
and recommended in some obstetric haemorrhage algorithms,33
34 would result in many women with normal haemostasis
receiving FFP, potentially contributing to adverse effects whilst
not affecting haemostasis.
In this study, fewer women were randomized with a fibrino-
gen <2 g litre1 than expected. This is probably because of chal-
lenges related to consenting women with severe bleeding and
undertaking trial procedures whilst treating acutely ill women.
This may have excluded women most likely to respond to
Table 2 Haematological parameters over time (study entry, prior to randomization, 15min and 24h after study medication). *Adjusted for
value prior to randomization. The median (25th–75th centile) number of vials of study medication infused was 3 (3–4) in the fibrinogen
group and 4 (3–5) in the placebo group. PT, prothrombin time; aPTT, activated partial thromboplastin time
Fibrinogen (n¼28) Placebo (n¼27) Adjusted* difference
in means (95% CI)
P-value
Fibtem A5 (mm), mean (SD)
Study entry 13.9 (2.6) 13.2 (4.0) – –
Prior to randomization 12.5 (2.2) 11.2 (2.7) – –
15min after study medication 16.8 (3.8) 10.5 (3.6) 5.6 (3.5–7.7) <0.001
24h after study medication 20.8 (4.2) 17.8 (3.6) 2.2 (0.02 to 4.4) 0.052
Clauss fibrinogen (g litre1), mean (SD)
Study entry 2.6 (0.5) 2.9 (0.6) – –
Prior to randomization 2.6 (0.7) 2.6 (0.6) – –
15min after study medication 3.2 (0.9) 2.3 (0.7) 0.9 (0.5–1.3) <0.001
24h after study medication 4.1 (0.8) 4.0 (0.9) 0.02 (0.5 to 0.5) 0.950
PT (s), mean (SD)
Study entry 11.8 (2.1) 11.3 (1.6) – –
Prior to randomization 12.1 (2.1) 11.6 (1.8) – –
15min after study medication 12.4 (2.1) 12.0 (2.0) 0.2 (0.8 to 0.2) 0.332
24h after study medication 11.9 (2.4) 11.5 (1.4) 0.1 (0.7 to 1.1) 0.735
aPTT (s), mean (SD)
Study entry 27.0 (5.0) 26.2 (5.0) – –
Prior to randomization 28.4 (5.0) 27.2 (7.4) – –
15min after study medication 28.8 (4.7) 30.5 (7.0) 3.9 (7.4 to 0.4) 0.029
24h after study medication 30.5 (4.6) 30.1 (4.0) 0.1 (2.2 to 1.9) 0.892
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fibrinogen replacement. Future studies will need to consider
strategies to ensure inclusion of all eligible patients.
Fibrinogen concentrate rather than cryoprecipitate was used
because it could be mixed and given within 10min and allowed
the intervention to be blinded.22 Fibtem A5 was used to facilitate
early infusion of fibrinogen concentrate. Our study supports the
feasibility of managing severe obstetric haemorrhage using
Fibtem but does not address cost effectiveness.
All women received prophylactic tranexamic acid; the effect
of fibrinogen concentrate in the absence of this drug is
Table 3 Secondary study outcomes. *Effect estimates from the unadjusted model are displayed as site, Caesarean section and platelet
count at the time of randomization had no effect on these study outcomes. †Odds ratio (OR) of the fibrinogen arm compared with placebo
arm. An OR< 1 indicating a higher proportion in placebo compared with the fibrinogen and an OR> 1 indicating a higher proportion in
the fibrinogen compared with the placebo. ‡Incidence rate ratio (IRR) of the fibrinogen arm compared with placebo arm. An IRR <1 indicat-
ing a higher incidence rate of transfusions in placebo compared with the fibrinogen arm and an IRR >1 indicating a higher incidence rate
of transfusions in the fibrinogen arm compared with the placebo. ¶Data were transformed before modelling using log plus one transfor-
mation. §Data were log transformed due to skewed distribution. The estimate should be interpreted as a ratio of logs (fibrinogen:placebo)
rather than a difference. kHazard ratio (HR) of the fibrinogen arm compared with placebo arm. A HR< 1 indicating a higher duration in the
placebo compared with the fibrinogen arm and a HR> 1 indicating a higher duration in the fibrinogen arm compared with the placebo.
NA, not analysed because of insufficient data for analysis in regression model; RBC, red blood cell; FFP, fresh frozen plasma
Fibrinogen (n¼28) Placebo (n¼27) Unadjusted* treatment
effect estimate (95% CI)
P-value
Allogeneic blood products transfused between study drug completion and date of discharge
No allogenic products transfused, n (%) 13 (46.4) 12 (44.4) 0.92† (0.32–2.67) 0.88
RBC transfusions
Total number 37 38
Mean transfusion rate (total transfusions/n) 1.32 1.41 0.94‡ (0.44–2.02) 0.87
Median (25th–75th centile) 1 (0–2) 1 (0–2)
Range 0–9 0–8
No RBC transfused, n (%) 13 (46.4) 13 (48.1)
FFP transfusions
Total number 18 33
Mean transfusion rate (total transfusions/n) 0.64 1.22 0.53‡ (0.13–2.16) 0.37
Median (25th–75th centile) 0 (0–0) 0 (0–2)
Range 0–4 0–8
No FFP transfused, n (%) 22 (78.6) 19 (70.4)
Platelet transfusions
Total number 2 3
No platelets transfused, n (%) 27 (96.4) 24 (88.9) NA
Cryoprecipitate transfusions
Total number 1 1
No cryoprecipitate transfused, n (%) 27 (96.4) 26 (96.3) NA
Measured abnormal blood loss (ml):
Within 24h of study medication
Median (25th–75th centile) 225 (100–341.25) 300 (60–800) 0.25§ (1.35 to 0.85) 0.66
Range 0–1465 0–3000
Between study medication and date of discharge As above As above
Invasive procedures after study medication, n (%)
Within 24h of study medication 4 (14.3) 5 (18.5) 0.73† (0.17–3.08) 0.67
Between study medication and date of discharge 5 (17.9) 5 (18.5) 0.96† (0.24–3.77) 0.95
Level 2 care
Admitted to level 2 care, n (%) 27 (96.4) 24 (88.9) 3.38† (0.33–34.65) 0.31
Length of stay (h), median (25th–75th centile) 16.0 (12.0–25.0) 20.5 (10.5–28.5) 0.03§ (0.48 to 0.42) 0.90
Range 2–152 1.5–88
Level 3 care
Admitted to level 3 care, n (%) (7.1) 2 (7.4) 0.003† (0.14 to 0.13) 0.97
Length of hospital stay (days)
Median (25th–75th centile) 3.0 (2.0–5.0) 3.0 (2.0–4.0) 0.23§ (0.07 to 0.52) 0.13
Mean (SD) 2.89 (1.05) 4.50 (4.37)
Range 1–23 1–6
Breastfeeding at 6week follow-up
Ever breastfed, n (%) 17 (68.0) 19 (79.2) 0.56† (0.15–2.04) 0.38
Missing 3 3
Breastfeeding/expressing at time of interview 10 (60.0) 12 (68.4) 1.00† (0.23–4.28) 1.00
Stopped breastfeeding 5 (40.0) 6 (31.6)
Missing 2 1
Duration of breastfeeding (days), median (25th–75th centile) 37 (0–46) 43 (0.5–60) 0.94§ (0.39–2.28) 0.89
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unknown. No significant safety issues were raised although the
study was not powered to detect these. There were two throm-
botic events, one in each of the placebo and fibrinogen groups.
In conclusion, infusion of fibrinogen concentrate triggered
by Fibtem A515mm did not improve outcomes. Subgroup
analyses suggest that fibrinogen replacement is not required if
Fibtem is >12mm or fibrinogen is >2–2.5 g litre1, but an effect
below those levels cannot be excluded. Studies are required that
randomize women to fibrinogen replacement with Fibtem/fibri-
nogen <12mm/2.5 g litre1 to investigate whether this is clini-
cally and cost effective.
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Fibrinogen
(n¼28)
Placebo
(n¼27)
Unadjusted treatment
effect estimate (95% CI)
Interaction term
P-value
Total allogeneic blood products after study medication until discharge, units
Fibtem A5 at randomization
12mm n¼13 n¼15
Median (25th–75th centile) 1.0 (0.0–4.5) 3.0 (0.0–6.0) 0.59* (0.19–1.84)
>12mm n¼15 n¼12 0.135
Median (25th–75th centile) 1.0 (0.0–2.0) 0.0 (0.0–1.0) 2.13* (0.64–7.06)
Missing 0 0
Fibrinogen at randomization
<2 g litre1 n¼3 n¼4
Median (range) 1.0 (1.0–15.0) 7.0 (3.0–23.0) 0.57* (0.14–2.36)
2 g litre1 n¼21 n¼18 0.458
Median (range) 0.0 (0.0–8.0) 0.0 (0.0–6.0) 1.31* (0.44–3.92)
Missing 4 5
Measured abnormal blood loss 24h after study medication (ml)
Fibtem A5 at randomization
12mm n¼13 n¼15
Median (25th–75th centile) 300 (100–350) 700 (200–1550) 1.04† (2.17 to 0.08)
>12mm n¼15 n¼12 0.078
Median (25th–75th centile) 200 (55–355) 155 (1.25–525) 0.81† (0.94 to 2.56)
Fibrinogen at randomization
<2 g litre1 n¼3 n¼4
Median (range) 300 (100–745) 1770 (700–3000) 1.73† (2.73 to 0.73)
2 g litre1 n¼21 n¼18 0.329
Median (range) 200 (0–1465) 230 (0–1700) 0.14† (1.47 to 1.19)
Missing 4 5
Time in level 2/3 care (h)
Fibtem A5 at randomization
12mm n¼13 n¼15
Median (25th–75th centile) 15 (9.25–26.5) 22 (10.0–29.0) 0.19† (0.63 to 1.01) 0.850
>12mm n¼15 n¼12
Median (25th–75th centile) 16.0 (13.0–25.0) 16.5 (8.0–26.75) 0.29† (0.43 to 1.02)
Fibrinogen at randomization
<2 g litre1 n¼3 n¼4
Median (range) 15 (10–320) 30 (1.5–74) 0.36† (0.91 to 1.63)
0.402
2 g litre1 n¼21 n¼18
Median (range) 15 (2–20) 18 (0–88) 0.005† (0.56 to 0.57)
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Supplementary material is available at British Journal of
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